Homology Medicines Inc. (FIXX)
NASDAQ: FIXX
· Real-Time Price · USD
0.93
0.00 (0.26%)
At close: Mar 25, 2024, 9:00 PM
Homology Medicines Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | -1.42M | n/a | n/a | 1.42M | n/a | 354K | 802K | 802K | 802K | 802K | 802K | 802K | 1.68M | 2.19M | 29.3M |
Cost of Revenue | n/a | 1.42M | n/a | n/a | 1.29M | 136K | 564K | 587K | 633K | 635K | 786K | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | 5K | n/a | n/a | 131K | -136K | -210K | 215K | 169K | 167K | 16K | 802K | 802K | 1.68M | 2.19M | 29.3M |
Operating Income | -12.23M | -10.84M | -18.81M | -14.84M | -9.41M | -31M | -30.82M | -27.51M | -34.49M | -32.86M | -28.31M | -37.62M | -33.63M | -30.66M | -30.55M | -1.11M |
Interest Income | n/a | -2.6M | n/a | n/a | 1.18M | 1.42M | 1.51M | 1.47M | 1.46M | 1.27M | 474K | 32K | 42K | 53K | 52K | 38K |
Pretax Income | -11.03M | -15.56M | -17.59M | 1.21M | -2.15M | -29.58M | -29.3M | -26.04M | -33.04M | -31.59M | -27.83M | 93.66M | -33.58M | -30.61M | -30.5M | -1.07M |
Net Income | -11.03M | 1.98M | -17.59M | 1.03M | -16.12M | -32.95M | -35.04M | -28.84M | -32.94M | -31.55M | -27.73M | 92.11M | -33.58M | -30.61M | -30.5M | -1.07M |
Selling & General & Admin | 5.1M | 1.79M | 4.47M | 5M | 7.9M | 6.84M | 8.19M | 8.32M | 8.15M | 7.81M | 8.03M | 14.15M | 10.78M | 8.35M | 9.04M | 8.66M |
Research & Development | 7.12M | 19.27M | 14.35M | 9.84M | 1.51M | 17.52M | 22.98M | 19.99M | 27.15M | 25.85M | 21.07M | 24.27M | 23.65M | 23.99M | 23.7M | 21.75M |
Other Expenses | n/a | n/a | n/a | n/a | 2.69M | 6.64M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 12.23M | 21.06M | 18.81M | 14.84M | 9.41M | 31M | 31.17M | 28.31M | 35.3M | 33.66M | 29.11M | 38.42M | 34.43M | 32.34M | 32.74M | 30.42M |
Interest Expense | n/a | -1.47M | n/a | n/a | 1.47M | n/a | n/a | n/a | n/a | 1.27M | 474K | 32K | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | n/a | 22.48M | n/a | 14.84M | 9.41M | 31M | 31.17M | 28.31M | 35.3M | 33.66M | 29.11M | 38.42M | 34.43M | 32.34M | 32.74M | 30.42M |
Income Tax Expense | n/a | -17.54M | n/a | 176K | 13.96M | 3.38M | 5.74M | 2.8M | -101K | -46K | -105K | 967K | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 12.2M | 9.32M | 5.16M | 995.28K | 322.32K | 321.41K | 321.08K | 320.65K | 319.35K | 317.57K | 316.87K | 318.22K | 316.78K | 314.9K | 313.79K | 279.8K |
Shares Outstanding (Diluted) | 12.2M | 9.66M | 6M | 2.33M | 322.32K | 321.41K | 321.08K | 320.65K | 319.35K | 319.15K | 318.81K | 321.53K | 317.26K | 317.26K | 313.87K | 279.8K |
EPS (Basic) | -0.9 | 0.21 | -3.41 | 1.03 | -50.01 | -102.53 | -109.14 | -89.96 | -103.14 | -99.34 | -87.51 | 289.44 | -106.01 | -97.2 | -97.2 | -3.83 |
EPS (Diluted) | -0.9 | 0.20 | -2.93 | 0.44 | -50.01 | -102.53 | -109.14 | -89.96 | -103.14 | -98.85 | -86.97 | 286.46 | -105.85 | -96.48 | -97.17 | -3.83 |
EBITDA | -12.23M | -17.24M | -18.81M | -14.84M | -1.26M | -17.59M | -30.6M | -27.29M | -34.2M | -32.23M | -27.98M | -37.62M | -31.55M | -28.56M | -28.45M | 969K |
EBIT | n/a | 686K | n/a | -14.84M | -686K | n/a | -30.82M | -27.51M | -34.81M | -30.32M | -27.36M | 93.69M | -33.63M | -30.66M | -30.55M | -1.11M |
Depreciation & Amortization | n/a | -208.81K | n/a | 29K | 43.81K | 136K | 217K | 225K | 296K | 321K | 328K | -130.9M | 2.07M | 2.1M | 2.1M | 2.08M |